LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

References

• GOLD [homepage on the Internet]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2017 Available from: http://goldcopd.orgAccessed December 7, 2016
   Google Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• PriceDMiravitllesMPavordIFirst maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysisNPJ Prim Care Respir Med2016261606127808096
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHA systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPDPulm Pharmacol Ther2016421627864038
   PubMed Web of Science ®Google Scholar
• BrusascoVReducing cholinergic constriction: the major reversible mechanism in COPDEur Respir Rev2006153236
   Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting b-agonists for stable COPD: a systematic reviewChest201214251104111022383666
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlRINVIGORATE investigatorsOnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD. A systematic reviewChest2014146230931724556877
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHA systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPDChest2015148239740725798635
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD study investigators. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141415123
   Web of Science ®Google Scholar
• ObaYLoneNAComparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regressionTher Adv Respir Dis20159131525586493
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationPLoS Med20096e100010019621070
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• HigginsJPAltmanDGGøtzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.02011 [updated March 2011]The Cochrane Collaboration Available from: http://training.cochrane.org/handbook
   Google Scholar
• BorensteinMHedgesLVHigginsJPTRothsteinHRIntroduction to meta-analysisChichester, West SussexJohn Wiley & Songs, Ltd2009
   Google Scholar
• AsaiKMinakataYHirataKQVA149 Once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE studyEur Respir J201342573392
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• LarbigMTaylorAFMaitraSSchubert-TennigkeitABanerjiDEfficacy and safety of IND/GLY (indacaterol/glycopyrronium) versus placebo and tiotropium in symptomatic patients with moderate- to-severe COPD: the 52-week RADIATE studyRespirology201520suppl 3A438
   Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCQHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable chronic obstructive pulmonary diseaseChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• JonesPMiravitllesMvan der MolenTKulichKBeyond FEV(1) in COPD: a review of patient-reported outcomes and their measurementInt J Chron Obstruct Pulmon Dis2012769770923093901
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGDonnerCFInhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung diseaseDrugs200565121595161016060696
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBCardiovascular events in patients with COPD: TORCH study resultsThorax201065871972520685748
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743
   PubMed Web of Science ®Google Scholar
• QuanjerPHRuppelGLLanghammerABronchodilator response in FVC is larger and more relevant than in FEV1 in severe airflow obstructionChest Epub20161228
   Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat((R)) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler((R)) (ENERGITO((R)) study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar